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Lung transplant patients have an increased risk of pulmonary embolism which is often associated with hypercoagulability
disorders.Wepresentacaseofsuddendeathresultingfrompulmonaryintravascularplateletthromboembolismfollowingasingle-
lung transplant.
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1.CaseReport
A 60-year-old woman was diagnosed with pulmonary
ﬁbrosis-like nonspeciﬁc interstitial pneumonia in 2004 by
surgical lung biopsy which revealed advanced pulmonary
ﬁbrosis and morphological changes in pulmonary hyperten-
sion. Clinically, she presented functional class III dyspnea
according to the NYHA classiﬁcation. Respiratory function
showed forced vital capacity (FVC) of 1.51liters (51% of
predicted), forced expiratory volume in 1 second (FEV1)
of 1.261 liters (58% of predicted), and FEV1/FVC of 84%.
The echocardiographic study did not show any signs of
pulmonary hypertension. During her progress she suﬀered
two episodes of spontaneous pneumothorax, requiring
drainage and pleural abrasion. She was diagnosed with
Sj¨ ogren’s syndrome (SS) by salivary gland biopsy owing
to dry mouth and scapular belt pain. As part of the
patient’s routine rheumatological care, a full immunoglob-
ulin antibody screen showed precipitating antibodies to
the extractable nuclear antigens Ro/SS-A. Other immuno-
logical tests including cryoglobulins, lupus anticoagulant,
antiphospholipid antibodies, and rheumatoid factor were
repeatedly negative prior to transplantation. Her medical
history included systemic arterial hypertension, hypertensive
cardiomyopathy, and severe asymptomatic diastolic dysfunc-
tion with conserved left ventricle function.
The patient was evaluated for a lung transplant in
January 2005 and, in March of the same year, was placed on
theactivewaitinglistforlungtransplantation.Arightsingle-
lung transplant was performed in December 2005, with no
intraoperative complications. Extracorporeal circulation was
not required and evolution in the intensive care unit was
satisfactory, with extubation at 24 hours. Bilateral pleural
drainage was inserted with scant serohematic production.
Subcutaneous low-molecular-weight heparin (LMWH) was
started at that time at a dose of 60mg every 24 hours.
On the fourth day posttransplant, she was transferred to
the pneumology ward where she remained afebrile and
hemodynamically stable. Blood analysis showed hematocrit
29%, platelets142000, prothrombin time 103%, normalliver
and kidney function Na+: 141mmol/L, K+: 4.7mmol/L.
Immunosuppressant treatment with i.v. 6-methyl-
prednisolone, cyclosporine A and azathioprine was started,
together with prophylaxis against opportunistic infections
with nebulized amphotericin B and i.v. ganciclovir.
Posttransplant ventilation/perfusion scintigraphy showed
good perfusion of the transplanted right lung (79.5%),
with a minimal defect in the middle lobe and global2 Journal of Transplantation
hypoperfusion of the native left lung (20.5%). The patient’s
general status was good, with occasional dry cough attacks.
Room air oxygen saturation was 94–96%. On the night of
the 6th postoperative day she presented severe pain in the
right hemithorax and sudden dyspnea, needing an increase
in oxygen requirements. A chest X-ray performed yielded
no signiﬁcant pathologic ﬁndings. She was maintained
with saturations of 92-93% with high oxygen ﬂow until
she presented cutaneous cyanosis, severe irreversible
desaturation, and cardiorespiratory arrest.
Orotracheal intubation was started with assisted ventila-
tion and cardiopulmonary resuscitation. The monitor trac-
ing showed atrioventricular blockage; an external pacemaker
was placed without success. Pericardiocentesis performed
ruled out eﬀusion or pericardiac tamponade. Ventricular
ﬁbrillation later appeared which was not reversed after
deﬁbrillation and adrenaline and atropine administration.
The patient died after more than one hour of resuscitation
measures.
A clinical autopsy requested showed multiple platelet
thromboemboli (Figures 1, 2,a n d3) dilating preacinar
vessels, intraacinar vessels, and alveolar capillaries of both
lungs, though primarily aﬀecting the grafted right lung.
2. Discussion
Infections, acute and chronic rejection, and diﬀuse alve-
olar damage have been described as frequent causes of
death in lung transplant recipients [1–3]. In the early
posttransplant period, other leading factors limiting survival
in these patients include primary graft failure, surgical
complications, and pulmonary hemorrhage. The prevalence
of venous thromboembolism (VTE) which includes deep
vein thrombosis (DVT) and pulmonary embolism (PE) in
lung transplant recipients has not been well established and
few data are available on the contribution of PE to acute
mortalityandmorbidityinthesepatients.Someauthorshave
reported that these patients have an increased risk of VTE,
which would vary between 8% and 22% according to the
series. VTE is often associated with an increased amount
of vascular trauma, higher levels of immunosuppression,
use of cyclosporine, hypercoagulability disorders, need for
cardiopulmonary bypass, longer ischemic time, older age,
female sex, cytomegalovirus disease, diabetes mellitus, pneu-
monia, rejection, central venous catheters, and recipients
with idiopathic pulmonary ﬁbrosis. The majority of VTEs
occur within the ﬁrst month to 3 months postoperatively [4–
8].
Most cases, like ours, are diagnosed at autopsy; thus, PE
may be an underrecognized complication contributing to
respiratory failure in the early post-lung transplant period.
Burns and Iacono [6] studied 126 autopsies of lung and
heart-lung transplant recipients and found a high prevalence
of PE (27%), especially in the early postoperative period
and in mechanically ventilated patients. Although PE was
a frequent ﬁnding on autopsy examination, it was a rare
primary cause of death (6.8%). PE more often aﬀected
Figure 1: Moderate dilatation of the lumen of a preacinar artery
(comparing its diameter with that of the adjacent bronchiole) that
is occluded by clear eosinophilic material arranged in bands, and
without red blood cells in its distal portion. Hematoxylin-eosin,
x25.
Figure 2: Pulmonary ﬁled at medium magniﬁcation showing two
intra-acinar vessels dilated by numerous puntiform, anucleated
eosinophilicstructures,muchsmallerinsizethanthoseofredblood
cells. Hemotoxylin-eosin, x100.
single-anddouble-lungrecipientscomparedwithheart-lung
recipients and preferentially aﬀected the allograft.
ThispatientwasdiagnosedofSS,anautoimmunedisease
with symptoms and serological ﬁndings often overlapping
with systemic lupus erythematosus (SLE). Thromboembolic
e v e n t sa r ec o m m o ni nS L E ,b u tn o ti nS S[ 9]. However, case
reports have been described in SS patients who developed
fulminant multiorgan disease due to thrombotic diathesis
[10].AssociationsbetweenSSandthepresenceofanthiphos-
pholipid antibodies have been reported. These antibodies
play a role in thrombosis by an eﬀect on platelet membranes,
endothelial cells, and clotting protein such as prothombin,
protein C, and protein S. Patients with antiphospolipid
syndrome (APS) may develop a broad spectrum of pul-
monary disease like PE, pulmonary hypertension, microvas-
cular pulmonary thrombosis, pulmonary capillaritis, and
alveolar haemorage [11]. This association might be a remote
possibility in our case since, on the one hand, the patient
had a prior negative full immunoglobulin antibody screen
except for anti-Ro/SS-A and, on the other hand, the patient
neverhadanythromboemboliccomplicationbeforethelung
transplant.Obviously,inthesepatientswhenconsideringtheJournal of Transplantation 3
Figure 3:ImmunohistochemicalstainingwithFactorXIIIastaining
the intravascular anucleated structures, showing the platelet origin
of the thrombus. Immunohistochemistry, Factor XIIIa, x250.
risk factors for thromboembolism, a full immunoglobulin
antibody screen prior to transplantation must be done.
Pathologic ﬁndings in our patient, with the presence of
multiple platelet thromboembolism in pulmonary vessels,
diﬀerclearlyfromthoseoftypicalPE.Toourknowledge,this
histologic ﬁnding has never been described previously in a
lung transplant recipient.
Massive platelet thromboembolism is a possible cause of
death in patients dying unexpectedly following recent liver
transplantation [11, 12]. The cause of this extensive platelet
activation in liver transplant recipients is uncertain and
may be multifactorial. Nontransplant patients who showed
these changes had a known coagulopathy or recognized
risk of embolic disease. In any event, and unlike our case,
those authors were able to show patent platelet consumption
antemortem in some of these patients, probably due to
factors such as hemorrhage or disseminated intravascular
coagulation, requiring in some cases platelet concentrate
transmission.
One possibility is that release of tissue thromboplastin
or cell debris from the ischemic donor liver may activate
platelet aggregation. Similarly, cross-clamping of the aorta
during emergency surgery has been shown to lead to a
raised incidence of pulmonary microembolism. Experimen-
tal procedures in animals cause a signiﬁcant fall in serum
ﬁbrinogen and result in some ﬁbrin and numerous platelet
thrombiandaggregateswithinthelungsasaresultoftrauma
to the endothelium and stasis [13]. Probably during lung
transplantation, hypoxia, metabolic acidosis, chronic lung
disease, and several mechanisms of platelet aggregation may
act synergistically and result in endothelial damage and
local activation of platelet aggregation in the lungs despite
prophylaxis with LMWH. Unfortunately, this phenomenon
may only become clinically evident when it causes severe
respiratory disease or death.
Finally, it should be emphasized that the diagnosis in
our case was made following examination of necropsic
material. Histologically, the characteristic involvement of
low-caliber pulmonary vessels suggests that the process
could be diagnosed in some cases by detailed study of the
transbronchialbiopsy.Nevertheless,webelievethattherapid
onsetoftheclinicalpicture,asoccurredinourpatient,hardly
supports the usefulness of this invasive technique.
We present a case of sudden death resulting from
pulmonary intravascular platelet thromboemboli following
a single-lung transplant in a patient with pulmonary ﬁbrosis
and SS who received adequate prophylaxis with LMWH.
Therefore, we believe that platelet thromboembolims should
be considered among the causes of sudden death early after
lung transplantation.
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